In the same line, fibroblast-secreted HGF activates both the MAPK and PI3K/AKT pathways contributing to BRAF-targeted therapies' primary resistance in melanoma and in a subset of colorectal and glioblastoma cancer cells (Straussman et al., 2012). The gene discussed is BRAF; the disease is melanoma.